Metformin Pharmacokinetics in Patients With Chronic and Acute Heart Failure

• Status: Unknown status
• Trial end date: 2018-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the pharmacokinetics of metformin in heart failure patients in acute and chronic state in relation to metformin transporter genotypes. Participants have heart failure and type 2 diabetes treated with metformin.

Hypothesis:

Primary: The renal clearance of metformin is decreased in acute state of congestive heart failure compared with chronic state.

Secondary: Metformin trough values in HF patients are influenced by polymorphisms in transporter genes relevant to the pharmacokinetics of metformin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aarhus University Hospital
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Patients with heart failure

• LVEF < 45% within 12 months prior to inclusion

• NYHA-class I, II, III or IV

• Ability to understand the written patient information and to give informed consent

• Diabetes Type 2 (and in metformin treatment for > 1 month)

• Stable dosage of metformin treatment for at least 1 week prior to examination

Exclusion Criteria:

• Age < 18 years

• Current abuse of alcohol or drugs